United States securities and exchange commission logo





                           August 19, 2022

       Kevin Boyle, Sr.
       Chief Executive Officer
       Alaunos Therapeutics, Inc.
       8030 El Rio Street
       Houston, TX 77054

                                                        Re: Alaunos
Therapeutics, Inc.
                                                            Registration
Statement Filed on Form S-3
                                                            Filed August 12,
2022
                                                            File No. 333-266841

       Dear Mr. Boyle:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Dillon
Hagius at 202-551-7967 with any questions.




                           Sincerely,


                           Division of Corporation Finance

                           Office of Life Sciences
       cc:                                              Melinda Lackey